review go get tough tough
get go pt
regeneron report sales/earn provid investor updat
compani came street-high sales/earn estim
exhibit comfort beat consensu commerci product eylea dupix
libtayo continu shine eylea dispatch anoth competitor dupix
risk/benefit deliveri profil shine even face libtayo
start form bedrock emerg oncolog growth powerhous pipelin
asset strateg nation interest like oncolog pain etc
best-in-class opinion sales/earn momentum benefit share
price near term pipelin valu could realiz bring growth
multipl closer histor averag updat pt stay bullish
report sales/earn street-high estim due
uncertainti around sanofi san fp joint ventur jv account
treatment earli april note comfort beat consensu
expect across top line also increas non-gaap oper margin
updat model reflect disrupt
tougher y/i comp
eylea growth commentari favor note slowdown
dme part busi due april brought
dme number reflect realiti howev also state
see seriou side effect eylea recent
dupix libtayo continu good trajectori dupi especi
continu go strength strength sale annual ex-
us ex-u growth lead sanofi collabor revenu line grow
strongli trend expect acceler next year import part
upgrad import differenti model vs consensu
clearli make case best-in-class pipelin among
peer given blockbust alreadi commerci eylea dupix
emerg oncolog powerhous believ investor give
pipelin enough valu given ennui around potenti eylea competit
subsid pipelin benefit growth multipl trade
note large-cap biotech price-to-earnings multipl expand
last coupl month investor begin appreci product
 start shine oper leverag start benefit
bottom-lin best-in-class pipelin re-rat could start
year price histori
base biopharmaceut compani
eye
diseas high cholesterol
also best-in-class
analyst certif import disclosur see disclosur
praluent litig continu binari outcom remov
dupilumab cemiplimab launch ramp line expect
abl minim margin contract slow
eylea growth cost launch dupixent/kevzara/praluent/
abl maintain adjust gm
patent issu either dupix kevzara
patient demonstr potenti uncommon sae
cusp strong sale growth
increas eylea penetr dme approv
launch fast uptak dupix asthma/oth allerg
condit approv launch fast uptak libtayo
potenti slow believ could follow
left jab acceler sale right hook oper
pdufa dupix atop dermat pediatr
plan clinic studi start june antibodi
cocktail treatment
potenti file late-stag lymphoma
adjust oper margin current get
dupilumab ad/asthma sarilumab launch progress
rapidli anticip
eylea penetr dme npdr bolster
sale growth mitig eventu wamd market share loss
praluent patent rule favor sale rebound faster
antibodi cemiplimab sale cscc
top-lin revenu shrink due slow eylea growth creat near-
term margin pressur new product launch
eylea competit make signific inroad core franchis
launch product dupix demonstr uncommon sae
price target employ composit valuat methodolog biotech compani util forward p/
 multipl npv adjust non-gaap estim earn sinc sector typic high-growth/high-expect aim
rank target compani base qualiti sale and/or earn growth vs peer group peer index nbi
expect earn growth next three five year expect higher termin multipl
adj ep due greater certainti qualiti sales/earn growth appli discount rate vs
peer group averag
risk includ slower expect eylea growth and/or continu opex increas creat near-term margin pressur slower
expect new product launch eylea competit risk regulatori delay non-approv emerg unexpect side effect
statement million except per opcovariancenet product sale includ net libtayo sanofi collabor bayer healthcar collabor technolog licens total research sell gener good collabor contract oper incom expens total oper adjust incom adjust invest interest expense- loss extinguish debt- incom incom incom tax adjust net non-gaap dilut dilut share
indicationdrugtimingmilestoneinflamm result phase portion phase studi eosinophil esophag dupix atop dermat pediatr patient age mma also submit result phase studi asthma pediatr patient age data phase studi us eu patient critic sever result phase studi copd atop updat result initi studi certain b-cell expand potenti pivot phase updat result initi studi multipl submiss plan later year libtayo first-lin nsclc follow posit os regulatori submiss libtayo advanc high-dos formul aflibercept wet dmeotherfasinumab ngf phase studi fasinumab patient enrol long-term safeti studi osteoarthr evinacumab submit homozyg famili hypercholesterolemia submiss sbla praluent adult patietn homozyg famili hypercholesterolemia hofh antibodi cocktail antibodi cocktail treatment plan clinic studi june diseasesgaretosmab activin-a regulatori submiss fop regulatori author plan submiss phase program pnh initi combin program alnylam cemdisiran outperform
revenu eylea product us cemiplimab us praluent collabor healthcar collabor licens outperform
statement million except per product sanofi collabor bayer healthcar collabor technolog licens total research sell gener good collabor contract oper incom expens total oper adjust incom adjust invest interest loss extinguish debt- incom incom incom tax expense- adjust net non-gaap dilut dilut share adjust comp gross oper incom tax outperform
npv cagrcommentstot revenu growth ebitda growth net incom growth y/i growth tax rate us adj ep compound-annual-growth-rate group index nbi indexp group adj ep compound-annual-growth-rate expect nbi index ep ltgpeer group termin price-to-earnings multipl multipl large-cap peer group opco estim us termin price-to-earnings multipl peer group sale ep growth upsidetermin valu us wacc peer group rang per bloomberg us discount rate adj ep price-to-earnings valuat outperform
stock price compani mention report
